![Figure 2. ABT-737 rescues clinical features of AML mice. (A) Kaplan-Meier survival curves showing prolonged survival of AML mice who completed treatment with ABT-737 (n = 26, red line), mice who failed to complete treatment (n = 10, blue line), and untreated mice (n = 63, black line) plotted from date of birth (P < .0001). (B) White blood cell counts (WBC) (pretreatment vs posttreatment, P < .0001), neutrophil counts (pretreatment vs posttreatment, P < .05), lymphocytes (pretreatment vs posttreatment, P < .0001), and platelet counts (PLT) (pretreatment vs posttreatment, P < .0001) are shown (mean ± standard deviation, n = 30 mice in the pretreatment and posttreatment groups; n = 31 in the untreated group). There were no significant differences between untreated and pretreatment AML groups. (C) Percentage AML BM blasts pretreatment and posttreatment after day 33 from start of treatment (n = 6 mice). Giemsa stained BM smears showing decreased marrow blasts after treatment (shown in low power [LP × 50 magnification]) and hematoxylin and eosin stained liver sections with infiltration in the untreated mice and clearance in the treated mice postday 33. Representatives of 3 mice: (D) differential survival of mice transplanted each with 107 spleen cells from AML untreated (black) or treated (red) mice into lethally irradiated FVB/N recipients (n = 5 in each group) (log-rank χ2 = 9.496; P < .005). (E) Significant reduction in the Lin-/Sca-1+/c-Kit+ (LSK) population of untreated (n = 12) and treated (n = 8) (P < .01); untreated mice analyzed compared with WT FVB/N mice (P < .01); treated compared with WT mice (n = 6) (P ∼ .1). (F) ABT-737 targets myeloid progenitors. Dot plots showing numbers of day 7 colony-forming unit–granulocyte macrophage per 3 × 104 cells plated per dish from BMs of diseased untreated and normal mice (P < .001); untreated compared with treated mice were statistically different (P < .01) (mean ± standard deviation of n = 4 mice analyzed postday 33). There was no statistical difference between the WT and post-ABT-737 treatment groups (P ∼ .3).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/122/16/10.1182_blood-2012-07-445635/4/2864f2.jpeg?Expires=1722720586&Signature=tNvX~-KPXuZTYf7b780JOrvAqfVQIikzds2sF1mLIMfZuUvikFUIUNw-dbCYKLDGxu51cx6sRX6AiGrxYhCNoAe43~DXhr~0WgA~kHEsZjBo5YC2l0YFqOeby-Kn231Kl1-JqHtQ2Jll1XHVpYIHoG8BGjcWi3GArLFJq~Nd-tUIV9AcSZPWlX9Sn3bc74gMeXf4Ywes-aZJCbyQw1OwjyL3uLErHXpBmQmXUNp1SPS7CHaquqnL3LKw5lAS4gUrmpN0vQMuUm8h4UStN1Wbh4tQheVX9rK9JodYGmrPs4o2-WD9N0tdho5FKRn56wi9g-Osbtu3IxyNYeX5GoZyFw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
ABT-737 rescues clinical features of AML mice. (A) Kaplan-Meier survival curves showing prolonged survival of AML mice who completed treatment with ABT-737 (n = 26, red line), mice who failed to complete treatment (n = 10, blue line), and untreated mice (n = 63, black line) plotted from date of birth (P < .0001). (B) White blood cell counts (WBC) (pretreatment vs posttreatment, P < .0001), neutrophil counts (pretreatment vs posttreatment, P < .05), lymphocytes (pretreatment vs posttreatment, P < .0001), and platelet counts (PLT) (pretreatment vs posttreatment, P < .0001) are shown (mean ± standard deviation, n = 30 mice in the pretreatment and posttreatment groups; n = 31 in the untreated group). There were no significant differences between untreated and pretreatment AML groups. (C) Percentage AML BM blasts pretreatment and posttreatment after day 33 from start of treatment (n = 6 mice). Giemsa stained BM smears showing decreased marrow blasts after treatment (shown in low power [LP × 50 magnification]) and hematoxylin and eosin stained liver sections with infiltration in the untreated mice and clearance in the treated mice postday 33. Representatives of 3 mice: (D) differential survival of mice transplanted each with 107 spleen cells from AML untreated (black) or treated (red) mice into lethally irradiated FVB/N recipients (n = 5 in each group) (log-rank χ2 = 9.496; P < .005). (E) Significant reduction in the Lin-/Sca-1+/c-Kit+ (LSK) population of untreated (n = 12) and treated (n = 8) (P < .01); untreated mice analyzed compared with WT FVB/N mice (P < .01); treated compared with WT mice (n = 6) (P ∼ .1). (F) ABT-737 targets myeloid progenitors. Dot plots showing numbers of day 7 colony-forming unit–granulocyte macrophage per 3 × 104 cells plated per dish from BMs of diseased untreated and normal mice (P < .001); untreated compared with treated mice were statistically different (P < .01) (mean ± standard deviation of n = 4 mice analyzed postday 33). There was no statistical difference between the WT and post-ABT-737 treatment groups (P ∼ .3).
